^
Association details:
| Biomarker: | CEACAM5 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | labetuzumab govitecan (IMMU-130) (Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
Published date:
02/01/2021
Excerpt:
CEACAM5 expression was enriched in NEPC...Labetuzumab govitecan induced DNA damage in CEACAM5+ prostate cancer cell lines and marked antitumor responses in CEACAM5+ CRPC xenograft models including chemotherapy-resistant NEPC….Our findings provide insights into the scope and regulation of CEACAM5 expression in prostate cancer and strong support for clinical studies of labetuzumab govitecan for NEPC.
DOI:
https://doi.org/10.1158/1078-0432.CCR-20-3396
